Rugiet Health Review

✗ Cons

• •ED-only / non-GLP-1-weight-loss — NOT within WLR's primary editorial scope; included for affiliate transparency only because Edwin's Katalys application for Rugiet is pending ($80 + 6 payouts as of 2026-05-28). The therapeutic link to obesity care is indirect (Esposito 2004 JAMA: weight loss improves erectile function in men with metabolic syndrome).
• •Flagship Rugiet Ready is a COMPOUNDED multi-ingredient formulation — verbatim per consumer page: 'Rugiet Ready is a compounded drug product and requires a prescription. Compounded drugs are not approved by FDA and do not undergo review or verification by FDA for safety, effectiveness, or quality.' The specific sildenafil + tadalafil + apomorphine triple combination has not been studied in published randomized trials.
• •Apomorphine for ED is OFF-LABEL — FDA-approved only for advanced-Parkinson's hypomobility (APOKYN, KYNMOBI). The sublingual ED indication (Uprima/Ixense) was withdrawn from FDA review in the early 2000s after a positive cardiovascular safety signal. Off-label compounded apomorphine has limited modern safety data.
• •Exact mg dose strengths NOT disclosed on consumer-facing pages — sildenafil mg, tadalafil mg, apomorphine mg are not surfaced before completing the questionnaire at start.rugiet.com. Buyers cannot compare dose against FDA-approved generic-Viagra (sildenafil 25/50/100mg) or generic-Cialis (tadalafil 2.5/5/10/20mg) without entering the intake flow.
• •Weight-loss product 'Weigh In' is a COMPOUNDED bupropion + naltrexone + metformin oral combination — NOT a GLP-1 / GIP receptor agonist. Bupropion + naltrexone is the FDA-approved branded combo Contrave (FDA-approved 2014); metformin is FDA-approved for type 2 diabetes (off-label for weight). The compounded triple-combo here is NOT FDA-approved and is therapeutically inferior to semaglutide/tirzepatide for weight loss.
• •State availability NOT enumerated publicly — Terms verbatim: 'Our Service is currently only available to individuals who are located in states in which we offer the Service.' No state-availability table surfaced anywhere on the site or in support.rugiet.com. states_available array left empty until state list confirmed.
• •Medical group / clinical network NOT named — Terms reference generic 'medical groups who provide healthcare services through the Platform' but no PA / PLLC name surfaces (vs Beluga Health P.A. disclosed by BraveRx/Coby/AVARA Rx, or OpenLoop Health disclosed by Taurus Meds). Medical director not identified by name or credential.
• •Pharmacy Hub LLC and Triad Rx are named in Terms but NOT cross-verified in /Users/weightlossrankings/src/data/pharmacies.json — grep returned zero hits for either entity, so 503A/503B status and state licensure cannot be independently verified within the WLR registry.
• •Refund policy is restrictive: refunds available only if medication has not been ordered at time of request; federal law prohibits returning dispensed prescriptions; bundle pricing receives only prorated refunds based on shipments received. No satisfaction-guarantee window stated.
• •LegitScript certification ID was NOT cross-verified at legitscript.com in this pass (search did not return a specific certified-website ID); flagged for the next 90-day re-check.
• •BBB profile was NOT located for Rugiet, Rugiet Health, or MSB Holdings Inc. in this verification pass.
• •Founding year, founders' names, and named medical leadership NOT disclosed on /about (page returned 404) — corporate transparency is partial.
• •Trustpilot full aggregate page (trustpilot.com/review/rugiet.com) returned HTTP 403 to WebFetch — the 4.3-star / 1,208-review figure is from the Ready product page and could not be independently confirmed against the Trustpilot canonical.